Biotech hits the brakes on their PhIII pivotal for a lead antibiotic as investigators track a high rate of kidney injuries
The Swiss biotech Polyphor is back with a fresh cautionary tale about the antibiotics sector.
Just days away from its first anniversary of an IPO $POLN that raised $165 million, the developer said late last week that it is halting enrollment in its pivotal trial of its antibiotic murepavadin for nosocomial pneumonia after investigators tracked high rates of acute kidney injury in their Phase III trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.